New LaunchApr 10, 2026, 08:16 AM
LifeMD Launches Eli Lilly's Foundayo™ Oral GLP-1 for Weight Management, Priced from $149/Month
AI Summary
LifeMD, Inc. has begun offering Foundayo™ (orforglipron), Eli Lilly's newly FDA-approved once-daily oral GLP-1 treatment, to eligible patients via its weight management program. This strategic move, facilitated through integration with LillyDirect®, expands LifeMD's portfolio of branded GLP-1 therapies and reinforces its position in the virtual weight management market. Foundayo is available at a starting self-pay price of $149 per month, with potential for commercially insured patients to pay as little as $25, and Medicare coverage expected by July 2026. The addition of Foundayo, approved on April 1, 2026, is expected to enhance patient access to affordable, high-quality weight management care.
Key Highlights
- LifeMD, Inc. is now offering Foundayo™ (orforglipron), Eli Lilly's once-daily oral GLP-1 treatment, to eligible patients through its weight management program.
- Foundayo received FDA approval on April 1, 2026, making it the second oral GLP-1 therapy approved for weight management.
- The starting self-pay price for Foundayo is $149 per month for the initial dosage, with commercially insured patients potentially paying as little as $25 per month via a Lilly savings card.
- Medicare coverage for Foundayo is anticipated to begin in July 2026, broadening access for eligible patients.
- LifeMD CEO Justin Schreiber stated the addition of Foundayo is a "landmark moment" and furthers the company's commitment to "expanding access to high-quality, affordable weight management care."
- The offering expands LifeMD’s portfolio of branded GLP-1 therapies from both Lilly and Novo Nordisk, strengthening its position in clinically guided weight management.
Price Impact
More from LFMD